Notice of Meeting, 28432 [2018-13116]

Download as PDF 28432 Federal Register / Vol. 83, No. 118 / Tuesday, June 19, 2018 / Notices would constitute a clearly unwarranted invasion of personal privacy. daltland on DSKBBV9HB2PROD with NOTICES Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; Immunity in the Elderly (R01). Date: July 9–10, 2018. Time: 9:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health LD30, 5601 Fishers Lane, Rockville, MD 20892. Contact Person: Julio Aliberti, Ph.D., Scientific Review Officer, Scientific Review Program, DEA/NIAID/NIH/DHHS, 5601 Fishers Lane, MSC–9823, Rockville, MD 20852, 301–761–7322, alibertijc@ niaid.nih.gov. Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; Maintaining Immunity after Immunization (U01). Date: July 11–12, 2018. Time: 8:30 a.m. to 2:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 5601 Fishers Lane, Rockville, MD 20892. Contact Person: Geetanjali Bansal, Ph.D., Scientific Reviewer Officer, Scientific Review Program, Division of Extramural Activities, Room 3G49, National Institutes of Health/ NIAID, 5601 Fishers Lane, MSC 9834, Bethesda, MD 20892–9834, (240) 669–5073, geetanjali.bansal@nih.gov. Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; NIAID INVESTIGATOR INITIATED PROGRAM PROJECT (P01). Date: July 11, 2018. Time: 1:00 p.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 5601 Fishers Lane, Rockville, MD 20892, (Telephone Conference Call). Contact Person: Raymond R. Schleef, Ph.D., Senior Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, Room 3E61, National Institutes of Health/NIAID, 5601 Fishers Lane, MSC 9823, Bethesda, MD 20892–9823, (240) 669–5019, schleefrr@niaid.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS) Dated: June 13, 2018. Natasha M. Copeland, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2018–13138 Filed 6–18–18; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES DEPARTMENT OF HOMELAND SECURITY Substance Abuse and Mental Health Services Administration Federal Emergency Management Agency Notice of Meeting [Docket ID FEMA–2018–0002; Internal Agency Docket No. FEMA–B–1830] Pursuant to Public Law 92–463, notice is hereby given that the Substance Abuse and Mental Health Services Administration’s (SAMHSA) Center for Substance Abuse Prevention’s (CSAP) Drug Testing Advisory Board (DTAB) will convene via web conference on August 8, 2018, from 9:00 a.m. EDT to 5:00 p.m. EDT. The board will meet in closed-session via web conference on August 8, 2018, from 9:00 a.m. EDT to 5:00 p.m. EDT to discuss the proposed Mandatory Guidelines for Federal Workplace Drug Testing Programs (hair specimens). Therefore, the meeting is closed to the public as determined by the Assistant Secretary for Mental Health and Substance Use, SAMHSA, in accordance with 5 U.S.C. 552b(c)(4) and (9)(B), and 5 U.S.C. App. 2, Section 10(d). Meeting registration information can be completed at https://snacregister. samhsa.gov/MeetingList.aspx. Web conference and call information will be sent after completing registration. Meeting information and a roster of DTAB members may be obtained by accessing the SAMHSA Advisory Committees website, https:// www.samhsa.gov/about-us/advisorycouncils/drug-testing-advisory-boarddtab or by contacting the Designated Federal Officer, CAPT Sean J. Belouin, USPHS. Committee Name: Substance Abuse and Mental Health Services Administration’s Drug Testing Advisory Board. Dates/Time/Type: August 8, 2018, from 9:00 a.m. to 5:00 p.m. EDT: CLOSED. Place: Web Conference. Contact: CAPT Sean J. Belouin, USPHS, Senior Pharmacology and Regulatory Policy Advisor, Division of Workplace Programs, 5600 Fishers Lane, Room 16N06D, Rockville, Maryland 20857, Telephone: (240) 276–2600, Email: sean.belouin@samhsa.hhs.gov. Carlos Castillo, Committee Management Officer, SAMHSA. [FR Doc. 2018–13116 Filed 6–18–18; 8:45 am] BILLING CODE 4162–20–P VerDate Sep<11>2014 17:55 Jun 18, 2018 Jkt 244001 PO 00000 Frm 00024 Fmt 4703 Sfmt 4703 Proposed Flood Hazard Determinations Federal Emergency Management Agency, DHS. ACTION: Notice. AGENCY: Comments are requested on proposed flood hazard determinations, which may include additions or modifications of any Base Flood Elevation (BFE), base flood depth, Special Flood Hazard Area (SFHA) boundary or zone designation, or regulatory floodway on the Flood Insurance Rate Maps (FIRMs), and where applicable, in the supporting Flood Insurance Study (FIS) reports for the communities listed in the table below. The purpose of this notice is to seek general information and comment regarding the preliminary FIRM, and where applicable, the FIS report that the Federal Emergency Management Agency (FEMA) has provided to the affected communities. The FIRM and FIS report are the basis of the floodplain management measures that the community is required either to adopt or to show evidence of having in effect in order to qualify or remain qualified for participation in the National Flood Insurance Program (NFIP). In addition, the FIRM and FIS report, once effective, will be used by insurance agents and others to calculate appropriate flood insurance premium rates for new buildings and the contents of those buildings. SUMMARY: Comments are to be submitted on or before September 17, 2018. ADDRESSES: The Preliminary FIRM, and where applicable, the FIS report for each community are available for inspection at both the online location https://www.fema.gov/preliminaryflood hazarddata and the respective Community Map Repository address listed in the tables below. Additionally, the current effective FIRM and FIS report for each community are accessible online through the FEMA Map Service Center at https:// msc.fema.gov for comparison. You may submit comments, identified by Docket No. FEMA–B–1830, to Rick Sacbibit, Chief, Engineering Services Branch, Federal Insurance and Mitigation Administration, FEMA, 400 C Street SW, Washington, DC 20472, DATES: E:\FR\FM\19JNN1.SGM 19JNN1

Agencies

[Federal Register Volume 83, Number 118 (Tuesday, June 19, 2018)]
[Notices]
[Page 28432]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-13116]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration


Notice of Meeting

    Pursuant to Public Law 92-463, notice is hereby given that the 
Substance Abuse and Mental Health Services Administration's (SAMHSA) 
Center for Substance Abuse Prevention's (CSAP) Drug Testing Advisory 
Board (DTAB) will convene via web conference on August 8, 2018, from 
9:00 a.m. EDT to 5:00 p.m. EDT.
    The board will meet in closed-session via web conference on August 
8, 2018, from 9:00 a.m. EDT to 5:00 p.m. EDT to discuss the proposed 
Mandatory Guidelines for Federal Workplace Drug Testing Programs (hair 
specimens). Therefore, the meeting is closed to the public as 
determined by the Assistant Secretary for Mental Health and Substance 
Use, SAMHSA, in accordance with 5 U.S.C. 552b(c)(4) and (9)(B), and 5 
U.S.C. App. 2, Section 10(d).
    Meeting registration information can be completed at https://snacregister.samhsa.gov/MeetingList.aspx. Web conference and call 
information will be sent after completing registration. Meeting 
information and a roster of DTAB members may be obtained by accessing 
the SAMHSA Advisory Committees website, https://www.samhsa.gov/about-us/advisory-councils/drug-testing-advisory-board-dtab or by contacting the 
Designated Federal Officer, CAPT Sean J. Belouin, USPHS.
    Committee Name: Substance Abuse and Mental Health Services 
Administration's Drug Testing Advisory Board.
    Dates/Time/Type: August 8, 2018, from 9:00 a.m. to 5:00 p.m. EDT: 
CLOSED.
    Place: Web Conference.
    Contact: CAPT Sean J. Belouin, USPHS, Senior Pharmacology and 
Regulatory Policy Advisor, Division of Workplace Programs, 5600 Fishers 
Lane, Room 16N06D, Rockville, Maryland 20857, Telephone: (240) 276-
2600, Email: [email protected].

Carlos Castillo,
Committee Management Officer, SAMHSA.
[FR Doc. 2018-13116 Filed 6-18-18; 8:45 am]
 BILLING CODE 4162-20-P